



Attn: Trading and Market Making/Legal and Compliance/Operations/Systems
UNIFORM PRACTICE ADVISORY (UPC #81-25) 08/11/2025 OMGA Liquidating
Inc (F/K/A Omega Therapeutics Inc (OMGAQ))

Notice has been received that the above Company's Combined Disclosure Statement and Chapter 11 Plan of Liquidation Proposed by the Debtor became effective on 08/08/2025. On the Effective Date, all Equity Interests shall be deemed canceled, extinguished, and discharged and of no further force or effect, and the Holders of Equity Interests shall not be entitled to receive or retain any property on account of such Interests.¹

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Market Operations – 1-866-776-0800.

¹ See e.g., *In re: OMGA Liquidating Inc F/K/A Omega Therapeutics Inc* Chapter 11 Case No. 25-10211 (BLS) Combined Disclosure Statement and Chapter 11 Plan of Liquidation Proposed by the Debtor